Logo

Intas Pharmaceuticals Entered into a Collaboration and License Agreement with mAbxience for Etanercept Biosimilar to Treat Autoimmune Diseases

Share this
Intas

Intas Pharmaceuticals Entered into a Collaboration and License Agreement with mAbxience for Etanercept Biosimilar to Treat Autoimmune Diseases

Shots: 

  • Intas Pharmaceuticals signed a strategic exclusive licensing agreement with mAbxience for Etanercept biosimilar for the treatment of autoimmune diseases 
  • Under the terms of the agreement, Intas receives the exclusive rights to commercialize Etanercept biosimilar across more than 150 countries worldwide, incl. Europe & the US, for the treatment of various autoimmune diseases. Moreover, mAbxience will be responsible for the development, manufacturing & distribution of the Etanercept biosimilar 
  • The financial terms of the transaction under the collaboration were undisclosed.  

Ref: PR Newswire Image: Intas

Related News:- Intas and Dong-A ST Report EMA Acceptance of MAA for DMB-3115, a Proposed Biosimilar to Stelara (ustekinumab)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions